SBI Securities’s Nektar Therapeutics NKTR Stock Holding History

SBI Securities’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$160K	Sell	2,639 -111	-4%	-$7.79K	﹤0.01%	737
2026 Q2	$192K	Buy	2,750 +2,609	+1,850%	+$191K	﹤0.01%	676
2026 Q1	$10.1K	Sell	141 -5	-3%	-$285	﹤0.01%	1712
2025 Q4	$6.17K	Sell	146 -10	-6%	-$560	﹤0.01%	1937
2025 Q3	$8.88K	Sell	156 -4	-3%	-$132	﹤0.01%	1821
2025 Q2	$4.13K	Buy	160 +137	+596%	+$1.54K	﹤0.01%	2079
2025 Q1	$238	Buy	23 +22	+2,200%	+$287	﹤0.01%	3155
2024 Q4	$13	Buy	+1	New	+$18	﹤0.01%	3898

Other funds holding NKTR

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return

LVW Advisors Pittsford, New York $1.19B AUM 19.73% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Activest Wealth Management Aventure, Florida $540M AUM 34.92% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

SBI Securities's NKTR Position: Q3 2026 in Review

SBI Securities reduced its Nektar Therapeutics (NKTR) stake by 4% in Q3 2026, selling an estimated $7.79K and leaving 2,639 shares worth $160K. The position accounts for ﹤0.01% of the portfolio, ranked #737.

SBI Securities first reported a position in NKTR in Q4 2024 and has held it in 8 quarters since. The position peaked at $192K in Q2 2026. 15 funds tracked by Wall St. Rank hold NKTR as of Q3 2026.

SBI Securities held 2,639 shares of Nektar Therapeutics worth $160K as of Q3 2026.
SBI Securities sold 111 Nektar Therapeutics shares in Q3 2026, an estimated $7.79K.
Nektar Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #737 holding.
SBI Securities first reported a position in Nektar Therapeutics in Q4 2024 and has held it in 8 quarters since.
SBI Securities's Nektar Therapeutics position peaked at $192K in Q2 2026.
15 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.